These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18541452)

  • 1. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine.
    Roldan R; Ruiz AM; Miranda MD; Collantes E
    Joint Bone Spine; 2008 Jul; 75(4):504-5. PubMed ID: 18541452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
    Calligaris L; Marchetti F; Tommasini A; Ventura A
    Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine.
    Ozen S; Bilginer Y; Aktay Ayaz N; Calguneri M
    J Rheumatol; 2011 Mar; 38(3):516-8. PubMed ID: 21159830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
    Portincasa P; Scaccianoce G; Palasciano G
    Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
    Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience.
    Ugurlu S; Ergezen B; Egeli BH; Selvi O; Ozdogan H
    Rheumatology (Oxford); 2021 May; 60(5):2327-2332. PubMed ID: 33295622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation.
    Moser C; Pohl G; Haslinger I; Knapp S; Rowczenio D; Russel T; Lachmann HJ; Lang U; Kovarik J
    Nephrol Dial Transplant; 2009 Feb; 24(2):676-8. PubMed ID: 19033248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
    Sargin G; Kose R; Senturk T
    Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
    Parlar K; Ates MB; Egeli BH; Ugurlu S
    Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.
    Giat E; Ben-Zvi I; Lidar M; Livneh A
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of anakinra in a patient with systemic amyloidosis presenting as amyloidoma.
    Nalcacioglu H; Ozkaya O; Genc G; Ayyildiz S; Kefeli M; Elli M; Aydin O; Ceyhan Bilgici M
    Int J Rheum Dis; 2018 Feb; 21(2):552-559. PubMed ID: 29239128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients.
    Marko L; Shemer A; Lidar M; Grossman C; Druyan A; Livneh A; Kivity S
    Rheumatology (Oxford); 2021 Jun; 60(6):2878-2883. PubMed ID: 34144604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab.
    Goto T; Miyazaki Y; Nakayamada S; Shiraishi N; Yoshinaga T; Tanaka Y; Nakamura T
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):237-242. PubMed ID: 35349715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.
    Mitroulis I; Papadopoulos VP; Konstantinidis T; Ritis K
    Neth J Med; 2008 Dec; 66(11):489-91. PubMed ID: 19075317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.
    Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A
    Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.